Charles River Labs (CRL) Stock
Key stats
- Market cap
- $16.42B
- Price / Earnings ratio
- 412.3x
- EPS (TTM)
- $1.07
- Volume
- Loading
- 52-week high
- $379.63
- 52-week low
- $146.20
- EPS vs analyst estimate
- +4.3%Q3 FY25 · $2.43 vs $2.33
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with CRL
Recent news

Charles River's Q3 Earnings on Deck: What's in Store for the Stock?
Charles River's Q3 Earnings on Deck: What's in Store for the Stock?
CRL

Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
CRL

Charles River Leverages Virtual Control Groups in GLP Studies
Charles River Leverages Virtual Control Groups in GLP Studies
CRL

Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
CRL
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 54.32
- MACD 12/26/9
- 9.95
- EMA 9 of MACD
- 12.37
- MACD histogram
- -2.42
- SMA 50
- $309.19
- Price above SMA 50
- EMA 50
- $313.67
- Price above EMA 50
- SMA 200
- $226.46
- Price above SMA 200
- EMA 200
- $243.53
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 10 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $2.66 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Charles River's Q3 Earnings on Deck: What's in Store for the Stock?
Charles River's Q3 Earnings on Deck: What's in Store for the Stock?
CRL

Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
CRL

Charles River Leverages Virtual Control Groups in GLP Studies
Charles River Leverages Virtual Control Groups in GLP Studies
CRL

Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
CRL

Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development
Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development
CRL

Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
CRL

PGNY or CRL: Which Is the Better Value Stock Right Now?
PGNY or CRL: Which Is the Better Value Stock Right Now?
CRL

Charles River Gains 75.8% in a Year: What's Driving the Rally?
Charles River Gains 75.8% in a Year: What's Driving the Rally?
CRL

Charles River and Autolomous Partner to Transform Laboratory Execution Systems
Charles River and Autolomous Partner to Transform Laboratory Execution Systems
CRL

Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan
Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan
CRL
News tone: automated (AI) classification of the article's content, not a price prediction.
About Charles River Labs
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Birgit Girshick | CEO & Director | 1970 |
| Mr. Glenn G. Coleman CPA | Corporate Executive VP & CFO | 1968 |
| Mr. Michael Gunnar Knell | Corporate Senior VP & Chief Accounting Officer | 1977 |
| Mr. Joseph W. LaPlume J.D. | Corporate Executive Vice President of Corporate Development & Strategy | 1974 |
| Ms. Victoria L. Creamer | Corporate Executive VP & Chief People Officer | 1970 |
| Mr. Mark Mintz | Corporate EVP, Chief Information Officer & Global Shared Services | 1974 |
| Mr. Todd Spencer | Corporate Vice President of Investor Relations | — |
| Ms. Kerry Dailey | Corporate Senior VP & Chief Legal Officer | — |
| Ms. Amy E. Cianciaruso | Corporate Senior Vice President, Chief Communications Officer & Government Relations | — |
| Dr. Brian F. Bathgate Ph.D. | Corporate Senior Vice President of European Safety Assessment | 1960 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 54.32
- MACD 12/26/9
- 9.95
- EMA 9 of MACD
- 12.37
- MACD histogram
- -2.42
- SMA 50
- $309.19
- Price above SMA 50
- EMA 50
- $313.67
- Price above EMA 50
- SMA 200
- $226.46
- Price above SMA 200
- EMA 200
- $243.53
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
10 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $295.00
- Average
- $346.80
- High
- $400.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -4.9 | +4.3 | ||||||||||
| 2022 | -8.9 | -13.2 | -0.2 | -16.3 | -4.8 | -6.8 | +14.5 | -17.8 | -3.2 | +4.2 | +10.3 | -3.7 |
| 2023 | +11.4 | -11.6 | -9.5 | -5.1 | +1.7 | +7.1 | +0.4 | -1.2 | -6.5 | -12.9 | +17.6 | +17.2 |
| 2024 | -7.7 | +15.8 | +2.5 | -14.8 | -10.4 | -0.6 | +20.1 | -18.6 | +2.6 | -8.0 | +10.0 | -8.3 |
| 2025 | -9.8 | +2.3 | -7.9 | -18.7 | +16.0 | +12.4 | +9.9 | -2.2 | -3.0 | +5.6 | -0.4 | +13.3 |
| 2026 | +4.0 | -16.3 | -3.4 | -4.5 | +9.0 | +24.6 | +1.5 | +24.8 | +4.5 | +25.3 | +1.2 |



